Menu Search
Equities

IDL Diagnostics AB (publ)

  • Add to watchlist
  • Add to portfolio
  • Add an alert
80R:FRA

IDL Diagnostics AB (publ)

Actions
  • Price (EUR)0.0222
  • Today's Change0.001 / 3.74%
  • Shares traded20.00
  • 1 Year change-44.50%
  • Beta1.0255
Data delayed at least 15 minutes, as of Feb 16 2026 07:09 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

IDL Diagnostics AB (publ), formerly AroCell AB (publ), is a Sweden-based diagnostic Company engaged in the biotechnology and medical diagnostics industry. The Company focuses on research, development, manufacturing, and commercialization of diagnostic and medical technology products. The Company has a broad product portfolio of In Vitro Diagnostics (IVD) tests that deliver clinical information for the detection of disease with indications spanning everything from urological cancers to typhoid fever. IDL Diagnostics AB (publ) develops tests that are clinically useful and economically viable. The Company provides rapid tests, laboratory tests and platform tests that improve decision making and are non-invasive, cost effective, as well as easy to perform.

  • Revenue in SEK (TTM)52.19m
  • Net income in SEK-39.31m
  • Incorporated2000
  • Employees22.00
  • Location
    IDL Diagnostics AB (publ)Karlsbodavagen 39BROMMA 168 67SwedenSWE
  • Phone+46 87996750
  • Websitehttps://arocell.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.